Novartis Takes option on Radius’ Osteoporosis Drug
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)
Published: 7 Oct-2007
DOI: 10.3833/pdr.v2007.i88.280 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Radius Health granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize all formulations of BA058 for treating postmenopausal osteoporosis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS